The multifocal cornea: offering better vision to patients with monofocal IOLs

The author proposes a new method for the correction of refractive residual defects for eye with monofocal pseudophakia in order to achieve spectacle independence.

Key Points

Multifocal IOLs represent an enormous advance in cataract surgery; they can offer patients independence from glasses and/or contact lenses. But what about those patients who have already received monofocal IOLs following cataract surgery? These patients often require glasses for near vision and, when combined with residual astigmatism or a refractive defect, they may also be dependent on glasses for distance vision.

We propose a new method for the correction of refractive residual defects for eyes with monofocal pseudophakia, with the creation of a multifocal cornea and correction of the refractive residual defect, in order to achieve spectacle independence for this group of patients.

Procedure & technique

The mean age of patients was 66 years (range: 59 to 74 years). Cataract surgery was performed, on average, 9.2 months preoperatively (range: 3.2 months and three years). Mean follow up was 7.8 months (range: 4.5 months to 15.5 months).

In 13 eyes the surgical technique was LASEK, while LASIK was performed in the remaining two eyes. The mean preoperative refractive defect measured as spherical equivalent was +1.64 (-0.94 to +2.77). All eyes underwent a complete ophthalmological evaluation preoperatively, including a wavescan examination and the same postoperative evaluation at one, three and six months and every three months thereafter.

It's all in the results

Related Videos
Trukera Medical rebranding ushers in new era of expansion into cornea market
Investigators report positive visual outcomes one year after monocular implantation of small aperture IOL
Investigating better indications and outcomes in laser refractive surgery
Avoiding errors when converting to DMEK
EDOF lens tech is evolving to help more patients with intermediate vision
Fixoflex ring: Prof. Pallikaris describes how to utilise the device during IOL implantation
Advancing IOL technology for treatment of presbyopia
Dexamethasone insert reduces time spent planning cataract surgery, counselling patients
Addressing gaps in vision care with a wearable diagnostic platform
Presbyopia-correcting drops provide hope for frustrated patients
© 2023 MJH Life Sciences

All rights reserved.